BK virus-associated hemorrhagic cystitis (BKV-HC) is a severe complication after allogeneic hematopoietic stem cell transplantation. So far, no specific antiviral drug with proven efficacy has been approved for treating BKV-HC. Leflunomide is an immunosuppressive drug with antiviral activity and has been used in treating BKV-associated nephropathy after renal transplantation. This is the first report on the efficacy and safety of leflunomide in the treatment of BKV-HC. From January 2006 to January 2009, 89 patients received allogeneic hematopoietic stem cell transplantation, and among them, 18 patients were identified as having BKV-HC, with a 20% cumulative incidence. Fourteen patients were treated with oral leflunomide. Three days of 100 mg/day leflunomide was used as loading doses and followed by maintenance doses of 20 mg/day. The urinary BKV-DNA load was monitored weekly by real-time quantitative PCR. The efficacy was evaluated on day 20 after leflunomide treatment. Seven patients (50%) achieved complete remission, 5 patients (35.7%) achieved partial remission, and 2 patients (14.3%) had more than a 1-log reduction in urinary BKV-DNA loads after treatment. During the leflunomide treatment, the graft-versus-host disease of the patients did not progress, and the dosages of the immunosuppressant were reduced simultaneously. One patient discontinued treatment because of intolerable gastrointestinal symptoms. Neutropenia occurred in 2 cases. These preliminary data suggest that leflunomide may be a potentially effective medication for treating BKV-HC without significant toxicity, but evidence supporting its use requires randomized controlled trials.

Keywords:
Allogeneic hematopoietic stem cell transplantation, BK virus, Hemorrhagic cystitis, Leflunomide
1.
Hassan Z, Remberger M, Svenberg P: Hemorrhagic cystitis: a retrospective single-center survey. Clin Transplant 2007;21:659–667.
2.
El-Zimaity M, Saliba R, Chan K: Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters. Blood 2004;103:4674–4680.
3.
Tsuboi K, Kishi K, Ohmachi K: Multivariate analysis of risk factors for hemorrhagic cystitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003;32:903–907.
4.
Arthur RR, Shah KV, Baust SJ: Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med 1986;315:230–234.
5.
Azzi A, Cesaro S, Laszlo D: Human polyomavirus BK (BKV) load and haemorrhagic cystitis in bone marrow transplantation patients. J Clin Virol 1999;14:79–86.
6.
Leung AY, Suen CK, Lie AK: Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood 2001;98:1971–1978.
7.
Giraud G, Bogdanovic G, Priftakis P: The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to the intensity of the conditioning regimen. Haematologica 2006;91:401–404.
8.
Dalianis T, Ljungman P: Full myeloablative conditioning and an unrelated HLA mismatched donor increase the risk for BK virus-positive hemorrhagic cystitis in allogeneic hematopoetic stem cell transplanted patients. Anticancer Res 2011;31:939–944.
9.
Savona MR, Newton D, Frame D: Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant. Bone Marrow Transplant 2007;39:783–787.
10.
Cesaro S, Hirsch HH, Faraci M: Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect Dis 2009;49:233–240.
11.
Farasati NA, Shapiro R, Vats A: Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 2005;79:116–118.
12.
Josephson MA, Gillen D, Javaid B: Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 2006;81:704–710.
13.
Hale GA, Rochester RJ, Heslop HE: Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. Biol Blood Marrow Transplant 2003;9:698–705.
14.
Przepiorka D, Weisdorf D, Martin P: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825–828.
15.
Leung AY, Yuen KY, Kwong YL: Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm. Bone Marrow Transplant 2005;36:929–937.
16.
Rinaldo CH, Hirsch HH: Antivirals for the treatment of polyomavirus BK replication. Expert Rev Anti Infect Ther 2007;5:105–115.
17.
Williams JW, Mital D, Chong A: Experiences with leflunomide in solid organ transplantation. Transplantation 2002;73:358–366.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.